Epidiolex 100 mg/mL Oral Solution
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Electrical Status Epilepticus of Slow-Wave Sleep
Conditions
Electrical Status Epilepticus of Slow-Wave Sleep
Trial Timeline
Mar 10, 2021 → Jan 17, 2024
NCT ID
NCT04721691About Epidiolex 100 mg/mL Oral Solution
Epidiolex 100 mg/mL Oral Solution is a phase 1 stage product being developed by Jazz Pharmaceuticals for Electrical Status Epilepticus of Slow-Wave Sleep. The current trial status is completed. This product is registered under clinical trial identifier NCT04721691. Target conditions include Electrical Status Epilepticus of Slow-Wave Sleep.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06924827 | Approved | Recruiting |
| NCT05485831 | Pre-clinical | Recruiting |
| NCT04721691 | Phase 1 | Completed |
Competing Products
1 competing product in Electrical Status Epilepticus of Slow-Wave Sleep
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ESES treated with clobazam | Lundbeck | Pre-clinical | 20 |